Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

Precision Epigenomics presents Episeek MCED test results at ASCO

August 2025—Precision Epigenomics presented validation data for its flagship multicancer early detection (MCED) test, Episeek, at the 2025 ASCO annual meeting in Chicago, May 30–June 3. The data demonstrated that the blood-based test is capable of identifying more than 60 cancer types with a 99.5 percent specificity rate and a turnaround time of two to three days. The test was validated on 281 cancer-positive plasma samples across all four stages and 201 samples from healthy people over 40 years old. It showed a 45 percent sensitivity for stage I/II cancers and a 74 percent sensitivity for stage IV cancers, with positive and negative predictive values of 64.9 percent and 99.5 percent, respectively.

Qiagen launches QIAseq, QIAcuity products

August 2025—Qiagen announced a series of product and partnership updates, including a new set of QIAseq panels for comprehensive genomic profiling, a QIAcuity digital PCR kit and assays for cell and gene therapy quality control, and a free, limited version of the Human Somatic Mutation Database from the Qiagen Digital Insights bioinformatics business.

CytoChip showcases CLIA-waived CitoCBC at ADLM

August 2025—CytoChip showcased its flagship product, CitoCBC, a cartridge-based CBC analyzer, at the Association for Diagnostics and Laboratory Medicine annual meeting, July 27–31, in Chicago. CitoCBC delivers rapid CBC results with a five-part white blood cell differential from a cartridge-based system and requires only monthly quality control.

CRCdx RAS mutation detection kit gets CMS coverage

August 2025—EntroGen announced that its CRCdx RAS mutation detection kit has received national coverage from the Centers for Medicare and Medicaid Services. CRCdx is an FDA-approved, real-time PCR-based companion diagnostic for use in identifying patients eligible for treatment with Vectibix (panitumumab), based on the absence of KRAS and NRAS mutations.

FDA approves Randox ConcizuTrace ELISA CDx

July 2025—The Food and Drug Administration has approved the de novo application for Randox Laboratories’ first companion diagnostic, the Randox ConcizuTrace ELISA. The test, developed in collaboration with Novo Nordisk, is intended for the quantitative measurement of concizumab-mtci concentration in human 3.2 percent citrated plasma samples from patients with hemophilia A and B four weeks after the initiation of treatment. The measurement of the concentration is used for dose adjustment decision in accordance with the drug label.

Bio-Rad presents workshops, demos at ADLM 2025

July 2025—Bio-Rad Laboratories will present an array of clinical diagnostic-related offerings at this year’s Association for Diagnostics and Laboratory Medicine Clinical Lab Expo in Chicago, July 27–31. An industry workshop titled “From Waste to Wow: Optimizing Your Quality Control Workflow” is designed to provide attendees with strategies to streamline QC management across multihospital systems for systemwide efficiency, reduce waste streams in clinical chemistry, and recognize patient-based real-time QC to improve lab QC processes.

StaffReady launches mobile app, website

July 2025—StaffReady has released a mobile app for its StaffReady Scheduling. The app is available on Apple and Android devices and offers StaffReady’s Calendar feature for users to easily view a schedule, request PTO, or make detailed shift requests, such as giveaways, trades, or bids. In addition, the company offers a weekly educational newsletter on its new website. It provides content specific to ancillary markets such as laboratories, pharmacies, and physical therapy/rehab departments and focuses on trends that affect workforce management in health care.

Techcyte launches wet mount iodine solution

July 2025—Techcyte announced the launch of its wet mount iodine solution for research use only in the United States. The AI-assisted screening tool is designed to help users locate, count, and preclassify parasites from iodine-stained fecal slides. The solution is part of Techcyte’s Fusion parasitology suite, which includes the company’s trichrome and modified acid fast solutions.

BioMérieux acquires Day Zero Diagnostics

July 2025—BioMérieux has agreed to acquire Day Zero Diagnostics, an infectious disease diagnostics company, with the aim of enhancing BioMérieux’s capabilities in next-generation sequencing and rapid diagnostics. Day Zero Diagnostics, based in Watertown, Mass., has developed technologies that integrate direct from whole blood sample preparation, sequencing, and advanced infectious disease and antimicrobial susceptibility testing analytics. The sequencing-based rapid diagnostic in development can identify the species and antibiotic resistance profile of a bacterial pathogen within hours.

Study validates Ibex Breast solution

July 2025—Ibex Medical Analytics reports that a study conducted at Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution, significantly improves accuracy and efficiency in evaluating breast pathology cases (Tahir M, et al. Clin Breast Cancer. Published online March 26, 2025). The study analyzed 104 real-world breast biopsies, including invasive and microinvasive carcinomas, ductal carcinoma in situ, atypical lobular hyperplasia, and other benign lesions. Three breast pathologists independently reviewed each case digitally, with and without the support of Ibex Breast. Results demonstrated that when using AI, diagnostic accuracy improved from 97.1 percent to 100 percent, with previously missed precancerous lesions, such as lobular neoplasia and microcalcifications, correctly identified.

MARKETPLACE

TRENDING